原发性高血压：一种口服血管紧张素转换酶抑制剂的作用
Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
作者信息
MacGregor G A, Markandu N D, Roulston J E, Jones J C
出版信息
Br Med J. 1979 Nov 3;2(6198):1106-9. doi: 10.1136/bmj.2.6198.1106.
Abstract
Captopril, a specific oral inhibitor of angiotensin-converting enzyme, was given to 18 unselected patients with moderate essential hypertension. Mean blood pressure fell by 14.5% at the maximum dose given, and this fall was significantly correlated with the initial plasma renin activity. The main fall in blood pressure occurred two hours after the first dose of captopril. These results suggest that captopril effectively lowers blood pressure in patients with essential hypertension and that the renin-angiotensin aldosterone system may maintain blood pressure in essential hypertension. This does not necessarily imply that the renin-angiotensin system is the cause of the high blood pressure.
摘要
卡托普利是一种特异性口服血管紧张素转换酶抑制剂，给予18例未经挑选的中度原发性高血压患者。在给予最大剂量时，平均血压下降了14.5%，且这种下降与初始血浆肾素活性显著相关。血压的主要下降发生在首次服用卡托普利两小时后。这些结果表明，卡托普利能有效降低原发性高血压患者的血压，且肾素-血管紧张素-醛固酮系统可能维持原发性高血压患者的血压。但这并不一定意味着肾素-血管紧张素系统是高血压的病因。
相似文献
1
Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.原发性高血压：一种口服血管紧张素转换酶抑制剂的作用
Br Med J. 1979 Nov 3;2(6198):1106-9. doi: 10.1136/bmj.2.6198.1106.
2
3
[Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].卡托普利抑制转化酶对原发性高血压患者动脉血压、肾素及醛固酮的影响
Arch Inst Cardiol Mex. 1982 Jul-Aug;52(4):295-300.
4
Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme.通过急性阻断血管紧张素转换酶测定肾素系统在顽固性高血压治疗中的作用。
Am J Nephrol. 1982;2(1):6-11. doi: 10.1159/000166575.
5
Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.卡托普利治疗临床高血压。肾素 - 血管紧张素系统各组分及身体成分的变化与血压下降的关系，并附关于转换酶抑制期间血管紧张素II测量的说明
Br Heart J. 1980 Sep;44(3):290-6. doi: 10.1136/hrt.44.3.290.
6
Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.血管紧张素转换酶抑制剂卡托普利对原发性高血压的作用。
Br J Clin Pharmacol. 1982 Feb;13(2):213-7. doi: 10.1111/j.1365-2125.1982.tb01359.x.
7
8
Treatment of moderate to severe hypertensive patients with an orally active converting-enzyme inhibitor.用口服活性转化酶抑制剂治疗中度至重度高血压患者。
Proc Eur Dial Transplant Assoc. 1979;16:603-9.
9
Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.原发性高血压中的血管紧张素转换酶抑制、儿茶酚胺与血流动力学
Am J Cardiol. 1982 Apr 21;49(6):1420-4. doi: 10.1016/0002-9149(82)90354-x.
10
Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.口服活性血管紧张素转换酶抑制剂卡托普利的血流动力学及降压作用
Hypertension. 1979 Jul-Aug;1(4):397-401. doi: 10.1161/01.hyp.1.4.397.
引用本文的文献
1
How adverse drug reactions can play a role in innovative drug research.药物不良反应如何在创新药物研究中发挥作用。
Pharm World Sci. 1995 Nov 24;17(6):195-200. doi: 10.1007/BF01870611.
2
Dose finding studies with imidapril--a new ACE inhibitor.新型血管紧张素转换酶抑制剂咪达普利的剂量探索研究。
Br J Clin Pharmacol. 1994 Mar;37(3):265-72. doi: 10.1111/j.1365-2125.1994.tb04274.x.
3
ACE inhibitors for heart failure: a question of dose.用于治疗心力衰竭的血管紧张素转换酶抑制剂：剂量问题。
Br Heart J. 1994 Sep;72(3 Suppl):S106-10. doi: 10.1136/hrt.72.3_suppl.s106.
4
Haemodynamic profile of captopril treatment in various forms of hypertension.卡托普利治疗各种类型高血压的血流动力学概况。
Eur J Clin Pharmacol. 1981;20(3):163-8. doi: 10.1007/BF00544593.
5
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.卡托普利：对其药理特性和治疗效果的初步综述。
Drugs. 1980 Dec;20(6):409-52. doi: 10.2165/00003495-198020060-00001.
6
Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol.卡托普利治疗原发性高血压；加用氢氯噻嗪或普萘洛尔的对比效果。
Br Med J (Clin Res Ed). 1982 Mar 6;284(6317):693-6. doi: 10.1136/bmj.284.6317.693.
7
Heart rate control in hypertensive patients treated by captopril.卡托普利治疗高血压患者的心率控制
Br J Clin Pharmacol. 1982 Dec;14(6):849-55. doi: 10.1111/j.1365-2125.1982.tb02048.x.
8
Captopril in Cushing's syndrome.卡托普利治疗库欣综合征
Klin Wochenschr. 1984 Sep 17;62(18):855-8. doi: 10.1007/BF01712002.
9
Angiotensin-converting enzyme and its clinical significance--a review.血管紧张素转换酶及其临床意义——综述
J Clin Pathol. 1983 Aug;36(8):938-47. doi: 10.1136/jcp.36.8.938.
10
Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.大鼠血浆肾素活性与MK 421降压作用的关系。
Br J Pharmacol. 1982 May;76(1):163-8. doi: 10.1111/j.1476-5381.1982.tb09202.x.
本文引用的文献
1
Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.在正常男性中用1- Sar，8- Ala血管紧张素II阻断和刺激肾、肾上腺及血管的血管紧张素II受体。
J Clin Invest. 1976 Jan;57(1):39-46. doi: 10.1172/JCI108266.
2
Clinical experience with use of ultrasound sphygmomanometer.超声血压计的临床应用经验。
Br Heart J. 1975 Aug;37(8):804-7. doi: 10.1136/hrt.37.8.804.
3
Agonist and antagonist effects of Sar1-ala8--angiotensin II in salt-loaded and salt-depleted normal man.Sar1-ala8-血管紧张素II在盐负荷及盐缺乏的正常人中的激动剂和拮抗剂作用
Br J Clin Pharmacol. 1976 Jun;3(3):483-7. doi: 10.1111/j.1365-2125.1976.tb00625.x.
4
Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects.高血压患者对1-肌氨酸-8-丙氨酸-血管紧张素II（沙拉新）的升压反应。
Circ Res. 1977 Mar;40(3):243-50. doi: 10.1161/01.res.40.3.243.
5
Measurement of plasma renin activity by radioimmunoassay after prolonged cold storage.长时间冷藏后通过放射免疫分析法测定血浆肾素活性
Clin Chim Acta. 1978 Aug 15;88(1):45-8. doi: 10.1016/0009-8981(78)90147-x.
6
Converting enzyme inhibition with an orally active compound in hypertensive man.在高血压患者中使用口服活性化合物进行转换酶抑制。
Hypertension. 1979 Jan-Feb;1(1):39-46. doi: 10.1161/01.hyp.1.1.39.
7
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.口服血管紧张素转换酶抑制剂SQ 14225对人体的降压作用。
N Engl J Med. 1978 May 4;298(18):991-5. doi: 10.1056/NEJM197805042981803.
8
Accentuated vascular and endocrine response to SQ 20881 in hypertension.高血压患者对SQ 20881的血管和内分泌反应增强。
N Engl J Med. 1977 Jul 28;297(4):184-8. doi: 10.1056/NEJM197707282970404.
9
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.血管紧张素转换酶特异性抑制剂的设计：新型口服活性抗高血压药物
Science. 1977 Apr 22;196(4288):441-4. doi: 10.1126/science.191908.
10
Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.评估肾素在高血压中的作用：转换酶抑制剂相对于沙拉新的优势。
Am J Med. 1976 Nov;61(5):790-6. doi: 10.1016/0002-9343(76)90160-1.
Zotero 插件